Retatrutide, from Soma, represents a exciting advance in body regulation. This innovative medication combines GLP-1 receptor agonist function with GIP receptor agonist engagement, showing substantial potential in clinical studies for metabolic improvement. Scientists believe the drug may offer a alternative solution for patients experiencing weight